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Transient TNF regulates the self-renewing
capacity of stem-like label-retaining cells in
sphere and skin equivalent models of melanoma
Pauline Ostyn1†, Raja El Machhour1†, Severine Begard1, Nuria Kotecki1, Jerome Vandomme1,2, Pilar Flamenco1,
Pascaline Segard1,2, Bernadette Masselot1,2, Pierre Formstecher1,2,3, Yasmine Touil1,4† and Renata Polakowska1*†
Abstract
Background: It is well established that inflammation promotes cancer, including melanoma, although the exact
mechanisms involved are less known. In this study, we tested the hypothesis that inflammatory factors affect the
cancer stem cell (CSC) compartment responsible for tumor development and relapse.
Results: Using an inducible histone 2B-GFP fusion protein as a tracer of cell divisional history, we determined that
tumor necrosis factor (TNF), which is a classical pro-inflammatory cytokine, enlarged the CSC pool of GFP-positive
label-retaining cells (LRCs) in tumor-like melanospheres. Although these cells acquired melanoma stem cell markers,
including ABCB5 and CD271, and self-renewal ability, they lost their capacity to differentiate, as evidenced by the
diminished MelanA expression in melanosphere cells and the loss of pigmentation in a skin equivalent model of
human melanoma. The undifferentiated cell phenotype could be reversed by LY294002, which is an inhibitor of
the PI3K/AKT signaling pathway, and this reversal was accompanied by a significant reduction in CSC phenotypic
markers and functional properties. Importantly, the changes induced by a transient exposure to TNF were
long-lasting and observed for many generations after TNF withdrawal.
Conclusions: We conclude that pro-inflammatory TNF targets the quiescent/slow-cycling melanoma SC compartment
and promotes PI3K/AKT-driven expansion of melanoma SCs most likely by preventing their asymmetrical self-renewal.
This TNF effect is maintained and transferred to descendants of LRC CSCs and is manifested in the absence of TNF,
suggesting that a transient exposure to inflammatory factors imprints long-lasting molecular and/or cellular changes
with functional consequences long after inflammatory signal suppression. Clinically, these results may translate into an
inflammation-triggered accumulation of quiescent/slow-cycling CSCs and a post-inflammatory onset of an aggressive
tumor.
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Background
Human malignant melanoma is an extremely aggressive
and drug-resistant skin cancer with poor prognosis if
detected at an invasive stage. Despite advances in melan-
oma research and drug development, 10-20% of clinically
disease-free patients relapse 510 years following an initial
treatment [1,2]. This phenomenon, which is known as
tumor dormancy [3], has been related to the existence of
therapy-resistant cells with stem-like activity [4-6]. Recent
findings suggest that cancer stem cells, in response to
chemotherapy, enter protective, prolonged, but reversible,
quiescence [7] and remain dormant without causing any
clinical manifestations until activated [8]. Once activated,
cancer stem cells (CSCs) are responsible for melanoma re-
initiation, tumor progression and increased tumor aggres-
siveness. Mechanisms that control quiescent tumor cell
activation remain poorly understood; however, cellular
interactions, the immediate microenvironment of various
diffusible factors or immune surveillance may be respon-
sible. The relatively well documented connection between
* Correspondence: renata.polakowska@inserm.fr
†Equal contributors
1Inserm U837 Jean-Pierre Aubert Research Center, Institut pour la Recherche
sur le Cancer de Lille (IRCL), 1, Place de Verdun 59045, Lille Cedex, France
Full list of author information is available at the end of the article
© 2014 Ostyn et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Ostyn et al. Cell Communication and Signaling 2014, 12:52
http://www.biosignaling.com/content/12/1/52
the incidence of cancer and chronic inflammation [9,10]
prompt us to study whether pro-inflammatory Tumor
Necrosis Factor (TNF) is involved in the phenotypic switch
of quiescent tumor cells into their active proliferative state
in melanoma. This cytokine, which was discovered by
Carswell et al. [11], is considered one of the major media-
tors of inflammation responsible for the development of
many cancers [12,13], including melanoma, upon exposure
to ultraviolet radiation [14]. Using an inducible H2B-GFP
tracing system, we demonstrated for the first time that
TNF increases the sub-population of quiescent or slow-
cycling melanoma stem-like cells. This increase was asso-
ciated with the increased self-renewal and sphere-forming
abilities of melanoma cells in vitro and their tumor-like
founding capacity in an in vivo-like model of human skin
equivalents (SEs). More importantly, by a serial transplant-
ation of SE-tumor cells using sphere-forming assays, we
found that the tumor-founding cells maintain these TNF-
induced properties for generations after first exposure and
that this activity may be mediated by the PI3K/AKT signal-
ing pathway.
Results
Detection of label-retaining melanoma cancer stem cells
in vitro
Cancer stem cells (CSCs), similar to normal adult stem
cells (SCs), remain quiescent most of the time and only in-
frequently enter the cell cycle to self-renew and to produce
progeny committed to differentiation, composing most the
tumor mass. This situation renders CSCs unable to dilute
labels tracing a cell divisional history as fast as their transi-
ent amplifying (TA) progeny. Thus, these cells are recog-
nized as the label-retaining cells (LRCs) in the tumor mass
[15]. Using the in vivo study of Tumbar et al. [16] as a
prototype, we constructed a tetracycline-inducible plasmid
system expressing fused Histone B2 with Green Fluores-
cent Protein (H2B-GFP) and generated stably transfected
clonal HBL and SK-Mel28 human melanoma cell lines
(HBL-H2B-GFP and SK-Mel28-H2B-GFP, respectively).
Without tetracycline, these cells were GFP-negative
(Figure 1A, B), demonstrating that this system is not
leaky. After 24 h of incubation with tetracycline (pulse
period), 96.8% ± 0.98 of monolayer cells was labeled with
GFP. A parallel flow cytometry (Figure 1A) and live cell
imaging analysis (Figure 1B, C) determined that cells lost
the GFP-emitted fluorescence as the cells proliferated in
the tetracycline-free medium (chase period). Importantly,
cell cycle progression was not affected by the H2B-GFP
fusion protein ([17] and our observation). At day 9, 2.8% ±
1.8 of cells still retained their labels (Figure 1B, C); how-
ever, all cells eventually lost their labels (not shown),
indicating that the monolayer culture conditions are in-
compatible with long-term cellular quiescence and that all
cells divide, although some are slower than others.
To recapitulate the more tumor-like conditions, we
traced the GFP dilution in 3D sphere cultures formed
by the tetracycline-induced HBL-H2B-GFP and SK-Mel
28-H2B-GFP cells. After 7 days of chase in tetracycline-
free sphere-forming medium, only individual cells
within melanospheres retained a high level of GFP
(GFPhigh) (Figure 2A, left). Other cells fluoresced with a
different intensity (Figure 2A, right), revealing hetero-
geneity in the proliferation rate within melanosphere cells.
A double parameter flow cytometry assay evaluating a
proportion of EdU-positive (EdU+) S-phase cells in the
GFPhigh and GFP-negative (GFPlow) subsets of melano-
sphere cells established that the GFPhigh subset contained
significantly (p < 0.05) less EdU+ cells after 2 h of labeling
than their GFPlowHBL-H2B-GFP counterparts (Figure 2B).
Together with the above observations, an analogous
decrease (1.8-fold) in the EdU+GFPhigh subset of SK-
Mel28-H2B-GFP demonstrates the relative replicative
quiescence of GFPhigh cells. Reversibly quiescent or slow-
cycling cells were shown to have a SC phenotype [15,16,18].
A comparative flow cytometry analysis of stem cell markers
with the GFP content revealed that the GFPhigh melano-
sphere cell subset was enriched in cells expressing well
established melanoma stem cell markers, including ABCB5
[19], CD271 (p75NTR), [20] and VEGFR1 [21]; a marker of
neural crest stem cells, HNK1 (CD57) [22]; and Notch1,
which is a common marker for many stem cell types [23]
(Figure 2C). Figure 2D shows representative flow cytome-
try analysis for the ABCB5 marker. In summary, these
data demonstrate that the pool of GFPhigh melanosphere
cells is enriched in quiescent/slow-cycling melanoma SCs
that can be easily distinguished from their fast-cycling TA
GFPlow progeny.
Pro-inflammatory TNF increases the proportion of
label-retaining melanoma stem cells
Equipped with a tool that distinguishes stem from non-
stem cells and knowing that chronic inflammation pre-
disposes tissues to cancer [9,13], we aimed to determine
whether inflammation affects the SC pool in melanoma,
thus providing a missing link between inflammation
and tumor development. The most prominent and best-
characterized pro-inflammatory cytokine present in the site
of inflammation is TNF [24,25], and reversible quiescence
is one of the hallmarks of SCs. TNF dramatically decreased
the proportion of melanosphere cells resting in the quies-
cent G0 phase of the cell cycle, reaching the level of adher-
ent monolayer cultures (Figure 3A). This finding suggested
that TNF stimulates the cycling of quiescent melanoma
SCs. Because CSCs are defined by their LRC properties, we
determined the effect of TNF on the quiescent/slow-
cycling GFPhigh subpopulation in the untreated and
TNF-treated melanospheres formed by fluorescing HBL-
H2B-GFP and SK-Mel28-H2B-GFP cells. The proportion
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of gated live GFPhigh cells in the control HBL-H2B-GFP
and SK-Mel28-H2B-GFP melanospheres amounted to
4.3% ± 1.4 and 6.2% ± 0.2, respectively, and TNF aug-
mented their proportion to 9.2% ± 2.4 and 9.6% ± 1.5,
respectively (Figure 3B). This result suggests that TNF
expands the pool of LRC-GFPhigh cells in melanospheres
either by a few (not exhausting GFP fluorescence) rounds
of symmetric division or by suppressing cycling of dividing
melanoma SCs. When compared with the starting inten-
sity, a general decrease in the GFP fluorescence intensity
indicates that GFPhigh cells divide, thus favoring the former
possibility but not excluding the latter. Similar to normal
SCs, CSCs can be recognized by their ability to proliferate
as non-adherent tumor-like spheres, and a sphere-forming
unit (SFU) value is an approximate indicator of the size of
the SC pool [26-28]. We assessed the effect of TNF on the
sphere-forming ability of HBL-H2B-GFP and SK-Mel28-
H2B-GFP cells with the wild type and mutated BRAFV600E,
respectively. Mutated BRAFV600E is constitutively active in
approximately 50% of human melanomas, causing their un-
controlled proliferation [29]. TNF significantly stimulated
tumor-like sphere formation in both cell lines (Figure 3C),
indicating that the TNF effect is BRAFV600E-independent
and confirming that TNF expands the melanoma SC pool.
As expected for melanoma SCs, live GFPhigh cells over-
expressed ABCB5 and CD271 surface markers, conferring
their CSC phenotype [19,20,30], and consistently, TNF
significantly (p < 0.01) increased the pool of GFPhigh-
ABCB5high (Figure 3D) and GFPhighCD271high (2.0x ±0.2,
data not shown) cells in HBL-H2B-GFP and, to a lesser
extent, in SK-Mel28-H2B-GFP (1.6x ±0.2 and 1.7x ±0.6,
respectively, data not shown) cell lines. Altogether, these
data infer that TNF expands the pool of GFPhigh
ABCB5high CD271high sphere-initiating melanoma SCs.
Because spheres are more tumorigenic than their adherent
counterparts when grafted into severe combined immuno-
deficiency disease (SCID) mice [31] and because the CSC
compartment is responsible for tumor development and
for the severity of breast cancer [15], we presumed that
TNF also predisposes to melanoma and a higher tumor
burden by increasing in the CSC compartment.
TNF inhibits melanoma cell differentiation and induces
transferable changes affecting the size of the melanoma SC
pool in 3D tumor-like sphere and organotypic skin models
To determine functional consequences of the TNF-insti-
gated changes leading to the increase in GFPhigh cells with
the melanoma SC phenotype, we performed functional
Figure 1 Dividing cells with diluted Histone 2B-Green Fluorescent Protein (H2B-GFP) fusion protein monitoring cell divisional history.
HBL and SK-Mel28 melanoma cells were stably transfected with the “TET-ON” plasmid system (Materials and methods) to express inducible
H2B-GFP. A. Flow cytometry analysis of GFP fluorescence at day (D) 0, 2, 4 and 7. GFP-negative tetracycline-uninduced cells (black lines) served as
reference to gate their GFP-positive (green lines) counterparts. The numbers indicate the percent of GFP-positive cells in the total population.
B. Representative IncuCyte images of live cell video recordings made during 9 days of culturing and illustrating a progressive dilution of GFP.
Control - uninduced HBL-H2BGFP cells. Scale bar = 50 μm. C. Quantitative illustration of GFP dilution during 9 days of culturing.
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tests (Figure 4A) using tumor-like sphere cultures.
Tetracycline-induced (pulse) monolayer HBL-H2B-GFP
and SK-Mel28-H2B-GFP cells were used to generate
spheres in the presence or absence of TNF in tetra-
cycline-free (chase) medium for 7 days. Dissociated and
sorted quiescent (GFPhigh) and TA actively cycling
(GFPlow) untreated and TNF-treated melanosphere cells
were assayed for their ability to form secondary spheres
and colonies in the absence of TNF. This experiment was
designed to allow the identification of a TNF responding
subpopulation and the estimation of the proportion of
sphere-initiating CSCs in the first generation of melano-
spheres. The same number of sorted GFPhigh TNF-
exposed melanosphere cells produced more secondary
spheres (Figure 4B) and colonies (Figure 4C) than their
unexposed counterparts despite TNF absence. In con-
trast, exposed GFPlow cells formed fewer spheres and
colonies then their unexposed controls. This result
demonstrates 2 important events: one, that the transient
exposure to TNF induces changes that persist for genera-
tions after TNF withdrawal, and two, that this long-term
TNF effect is exclusively maintained by GFPhigh CSCs.
This finding suggests that TNF imprints transferable mo-
lecular changes that permanently affect the functionality
of the melanoma GFPhigh SC compartment.
To gain insight into the possible cellular mechanism(s)
by which TNF maintained its effect, we recapitulated
melanoma in an in vivo-like [32,33] skin equivalent (SE)
model, which is an alternative to animal models, using
sorted quiescent (GFPhigh) and fast-cycling (GFPlow) cells in
the presence or absence of systemic TNF for 3 weeks. Inter-
estingly, control GFPhigh HBL-H2B-GFP cells (Figure 4D)
and, to a lesser extent, SK-Mel28-H2B-GFP (not shown)
cells were capable of developing into the highly pigmented
assembly of cells resembling melanoma tumor in vivo. TNF
apparently limited this process in GFPhigh SEs and had no
effect on GFPlow SEs, which contained only a few pigmen-
ted spots. These data underline the superior tumor regen-
eration potential of the GFPhigh cells over their GFPlow
counterparts and suggests that chronic TNF either spe-
cifically eradicates the majority of GFPhigh cells in SEs or
suppresses their differentiation. The presence of some
pigmented spots in all SEs independent of the condition
indicates a differential cellular response to environmental
clues and suggests that both GFPhigh and GFPlow cell
compartments are heterogeneous and that the GFPlow
compartment contains a small subpopulation of cells
with SC activity but are phenotypically undistinguishable
from the non-stem GFPlow cells, ratifying our earlier find-
ings [34].
To resolve whether TNF eradicates or blocks GFPhigh
cell differentiation, SE cells were recovered and assayed
for their sphere-forming abilities. Apparently, GFPhigh
cells were not eradicated because these cells initiated
the formation of more spheres (Figure 4E) when de-
rived from TNF-treated SEs. Consistent with a study
by Landsberg et al. [35], this result indicates that TNF
Figure 2 Melanospheres contain a small subpopulation of
quiescent/slow-cycling GFPhigh label-retaining cells (LRCs) with a
melanoma stem cell phenotype. A. Representative melanospheres
(left panel, scale bar = 50 μm) formed by HBL-H2BGFP cells dividing at
different rates, as reflected by differences in the GFP fluorescence
intensity between dissociated melanosphere cells (right panel, scale
bar = 20 μm). B. GFPhigh melanosphere HBL cells cycle slower and
incorporate less EdU than their GFPlow counterparts. C. These GFPhigh
cells overexpress stem cell surface markers. Histogram illustrating the
ratio of expression of each marker in GFPhigh cells to their own GFPlow
controls, which were set at “1” and marked by the red interrupted line.
D. Representative histograms of flow cytometry data for the surface
ABCB5 marker in melanosphere HBL-H2BGFP cells. Upper histogram
illustrates GFP (green) fluorescence distribution in total population. R1
is a region encompassing GFP negative (black lines) and GFPlow subset
and R2 GFPhigh subpopulation (shaded). Lower histograms show ABCB5
distribution between GFPlow and GFPhigh (shaded) subpopulations. R3 is
a boundary drawn around ABCB5high cells within GFPlow subset and
R4 within GFPhigh subpopulation. Numbers indicate percentage of cells
with a particular phenotype.
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inhibited the melanoma GFPhigh cell differentiation fate.
However, in Landsberg et al. study, this effect was mas-
sively reversible at the molecular level. We concluded that
the TNF-induced changes targeting melanoma SC com-
partment are irreversible, at least at the functional level,
because the TNF-reduced pigmentation was linked to a
steadily increasing number of secondary and tertiary
spheres formed by the sorted GFPhigh cells dissociated
from the first generation TNF-treated melanosphere in
the absence of TNF (Figure 4E). A small effect of TNF on
GFPlow and unexposed melanosphere cells confirms the
existence of actively dividing CSCs [34,36] within the non-
SC GFPlow cell subset. However, their number tended to
decrease with further generations, suggesting that the
GFPlow cells in the TNF-free environment progressively
exhaust their sphere-initiation and repopulation capacity,
which is apparently well preserved by the GFPhigh cell
subset that seems to attain a TNF-exposure memory.
Interestingly, these capacities appear to be specifically
restricted by the SE environment since unexposed GFPlow
SE cells generated fewer spheres then unexposed GFPlow
sphere cells (Figure 4B vs 4E). Collectively, all the
above data demonstrated that melanoma cell lines
contain a small pool of GFPhighABCB5highCD271high,
quiescent/slow-cycling, self-renewing, melanoma stem-like
cells that lose their ability to differentiate when targeted
by TNF, even transiently, and that these cells appear to
transfer this effect to further generations and manifest
post-TNF exposure.
Inactivation of the PI3K/AKT signaling pathway abolishes
the TNF effect on the melanoma stem cell compartment
TNF-suppressed differentiation, which was accompanied
by an increase in GFPhighABCB5high sphere-initiating
melanoma SCs, strongly suggests that TNF blocks the
commitment of these cells to differentiation, favoring
their symmetric over asymmetric self-renewal. One of
the important regulators of SCs, including CSC fate, is
the AKT signaling pathway [37-39]. Among its multiple
functions, AKT has been shown to block the differen-
tiation of myeloid leukemia [40] and embryonic stem
cells [41]. A deregulated AKT signaling pathway is often
found in melanoma [42,43], and we previously demon-
strated that this pathway regulates melanoma SC quies-
cence [34]. Consistent with the previous findings,
TNF also phosphorylated AKT in melanosphere cells
(Figure 5A), and this phosphorylation was associated with
the suppression of the differentiation-related MelanA
Figure 3 TNF enlarges the stem-like cell compartment in human melanomas in vitro. A. TNF decreased the proportion of melanosphere
cells resting in the G0 phase of the cell cycle to the level found in adherent monolayer (ML) cultures. TNF (0.5 μg/ml) was added at the time of
seeding cells for a sphere-forming assay. After 7 days, melanosphere cells were dissociated, reacted with an anti-Ki67 primary antibody and an
anti-mouse Cy5 secondary antibody, and then stained with propidium iodide (PI) before performing the flow cytometry analysis. Ki67-negative
cells in the G0/G1 fraction were considered the G0 quiescent cells. B. Flow cytometry of dissociated melanosphere cells revealed that TNF
increased the proportion of GFPhigh cells. Representative dot plot data and the corresponding % of GFP-positive cells (left panel) and summary
histograms of all data (right panel). C. TNF stimulates stem cell-related sphere-forming abilities in HBL and SK-Mel28 melanoma cell lines. D. TNF
increases expression of ABCB5, which is a melanoma stem cell surface marker, in GFPhigh cells (GFPhighABCB5high) when compared to GFPhigh cells
in untreated controls (CTR) set at “1” for each cell line. ***p < 0.001; **p < 0.01; *p < 0.05.
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Figure 4 (See legend on next page.)
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expression overridden by LY294002, which is an in-
hibitor of the PI3K/AKT signaling pathway (Figure 5B).
These data suggested that AKT might mediate the
TNF-initiated inhibition of melanoma differentiation.
A significant (p < 0.001) reduction in the sphere-forming
capacity of melanosphere cells generated in the presence
of LY204002 (Figure 5C) demonstrated that the sustained
inactivation of AKT signaling reduced the melanoma SC
compartment most likely by switching from symmet-
ric to asymmetric self-renewal and by releasing the
TNF-suppressed differentiation fate of melanoma SCs.
Consistently, LY294002 suppressed the TNF-induced
upregulation of GFPhighABCB5high melanoma SCs
(Figure 5D), strongly supporting AKT involvement in
the TNF-mediated regulation of melanoma SC fate
determination and functionality. Finally, because TNF-
activated AKT targets NFκB, which is a well-known
mediator of TNF responses [44-46] that control SC
fate [47], and because NFκB can target AKT [48,49],
evidencing a cross-talk between these pathways [49,50],
we used the NFκB inhibitor BAY 117082 in combination
with TNF to form melanospheres. This inhibition should
distinguish which of the two pathways mediates TNF
responses. As shown in Figure 5D, the NFκB inhibitor did
Figure 5 TNF expands the subset of GFPhigh/ABCB5high melanoma stem-like cells through the AKT-signaling pathway. A. Representative
image of western blot (n = 2) analysis showing an increase in phosphorylated (p)-AKT in spheres formed by HBL melanoma cells cultured in the
presence of TNF (0.5 μg/ml). Actin served as a loading control. B. Representative fluorescent microscopy images showing that LY294002 (10 μM)
addition at sphere seeding in the presence or absence of TNF stimulates Melan A expression, and the morphological differentiation of
melanospheres was inhibited by TNF. For each condition spheres were collected from 24 wells before dissociation and immunocytochemistry
analysis. Scale bar = 20 μm. C. PI3K/AKT inactivation blocked the TNF-induced melanoma SC-related ability to form spheres. Melanospheres were
formed in the presence or absence of TNF (0.5 μg/ml) and LY294002 (10 μM). *p < 0.05; ***p < 0.001. The data represent 2 independent experiments in
3 repetitions. D. Flow cytometry data showing that the PI3K/AKT inhibitor LY294002 (10 μM) added at seeding decreased the proportion of TNF-induced
ABCB5high cells in melanospheres formed by TNF-treated HBL cells. Note that the NFκB inhibitor BAY 11–7082 (1 μM) did not repress TNF-mediated
induction. Data of at least 2 independents each combining spheres from 24 wells.
(See figure on previous page.)
Figure 4 Transient exposure to TNF induces irreversible functional changes in the GFPhigh stem-like cell compartment. A. Schematic
representation of the experimental design. Green nuclei refer to GFP-positive cells. B. TNF affects the pool of self-renewing GFPhigh cells.
Tetracycline-induced HBL-H2BGFP melanoma cells formed melanospheres in the presence or absence of TNF that 7 days later were dissociated,
and cells were sorted by FACS. The GFPhigh and GFPlow cells were assayed for their sphere- (B) and colony (C)-forming abilities in TNF-free
medium. The histograms represent accumulated data from 24 individual samples. C. Representative image of clonogenic assay. The numbers
indicate the % of colony-forming units. D. TNF blocks melanoma cell maturation. Representative skin equivalents (SEs) co-cultured with HBL
melanoma cells and untreated or treated with TNF (0.5 μg/ml) for 3 weeks with TNF added to fresh medium, which was changed every 3 days.
Experiments were repeated 3 times. E. Control (CTR-black) or TNF-treated (TNF-red) dissociated SE cells were evaluated for their ability to generate
successive generations of spheres in TNF-free medium. The first (G1), second (G2) and the third (G3) generation spheres were formed during
7 days. ***p < 0.001; **p < 0.01.
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not affect the TNF-induced upregulation of GFPhigh-
ABCB5high melanoma SCs, demonstrating that this effect
is linked to AKT rather than NFκB activation.
Discussion
Reversible cellular quiescence is a hallmark of SCs. This
ability protects these cells from a harsh environment
and prevents their exhaustion imposed by constant cycling
[18,51,52]. CSC entry into cellular quiescence and their
post-therapeutic persistence in an apparently dormant
state may be one reason why curing cancer remains diffi-
cult. Dormant cells can be activated and re-initiate tumor
growth locally and in distant metastatic sites [1,53]. The
exact molecular factors and cellular mechanisms govern-
ing the quiescence and activation of dormant CSCs have
been intensely investigated but remain unclear, highlight-
ing the requirement for additional research in this area.
Because inflammation has been functionally related to
cancer evolution and because inflammatory signals have
been shown to regulate the quiescence/activation of
cancer and normal SCs [8,10,47,54,55] but not much
is known concerning the circuitries connecting inflamma-
tion to melanoma development, we examined the effect of
TNF, which is one of the major mediators of cancer-
related inflammatory responses [9], on melanoma cell
quiescence and melanoma development in 3D tumor-like
sphere and in vivo-like reconstructed skin models. Using
an inducible H2B-GFP system to trace the cell divisional
history in vitro, we identified quiescent/slow-cycling
GFPhigh label-retaining CSCs in melanoma cell lines and
showed that transient and chronic TNF suppresses me-
lanoma SC differentiation while enriching for a GFPhigh
melanosphere-initiating CSC subpopulation many genera-
tions after TNF withdrawal. This finding is consistent with
a model in which inflammatory TNF signals imprint
transferrable changes in the melanoma SC subpopulation,
permanently affecting their fate and function and, conse-
quentially, their progressive post-TNF expansion. Because
the size of the CSC compartment is directly linked to a
tumor burden [56], by enlarging this compartment, TNF
may cause a predisposition to melanoma development
and evolution. Our findings suggest that TNF may achieve
this effect by activating the PI3K/AKT signaling pathway.
AKT signaling, which is often constitutively active in
melanoma cells and in other cancer cells, regulates many
cellular processes, including cell survival, metabolism
and cell cycle progression [37,57,58]. Interestingly, recent
findings indicate that AKT is a particularly important
determinant of SC function because AKT controls SC
quiescence, propagation and fate [37-40]. Recently, we
demonstrated that quiescent melanoma SCs exit the
G0 phase of the cell cycle in response to transient AKT
inactivation; however, their cycling subset enters the qui-
escent state, whereas sustained AKT inhibition suppresses
cell cycle progression [34]. In the present study, we found
that LY294002, which is an inhibitor of PI3K/AKT, spe-
cifically blocked the TNF-driven enrichment of melano-
spheres in GFPhigh label-retaining cells with the CSC
phenotype and activity. This inhibition was accompanied
by the acquisition of dendritic cell morphology and by the
overexpression of the melanocyte differentiation marker
MelanA. These data demonstrate that PI3K/AKT inactiva-
tion stimulated melanoma GFPhigh cell differentiation,
suggesting that TNF suppresses their commitment to
the differentiation fate by activating AKT, consequently
preventing asymmetric self-renewal and promoting
symmetric self-renewal of GFPhigh melanoma SCs. This
interpretation is consistent with the observed TNF-driven
increase in the proportion of GFPhigh cells and in the
sphere-forming efficiency as well as with the inhibition of
GFPhigh CSC melanogenesis in SEs and with the simultan-
eous acquisition of sphere-forming abilities by the SE mel-
anoma cells. Therefore, it appears that one mechanism by
which TNF and, in general, inflammation may cause
cancer predisposition is a blockage of the differentiation
fate in CSCs, at least partially preventing the generation of
their fast-cycling destined-to-differentiate progeny. Logic-
ally, this mechanism would maintain CSCs in their primi-
tive, quiescent/slow-cycling state and lead to their slow,
but continuous, accumulation particularly because the
TNF-induced changes seem to be perpetuated in the
offspring of CSCs after TNF withdrawal. Currently,
the mechanism of this event is unknown. Very recently
Wilson et al. [59] have reported that melanoma SC main-
tenance is dependent on ABCB5-dependent secretion
of Il1β another inflammatory cytokine. Is TNF-induced
ABCB5 part of this regulatory circuit? Importantly how-
ever, the precedence of the transient induction of heritable
changes after removing a stimulus has already been linked
to the epithelial-to-mesenchymal transition process, creat-
ing self-renewing breast cancer stem cells from a non-
stem cell population [60,61]. In another study, a memory
of transitory FGF had a long-lasting effect on the fibro-
blast response to the secondary FGF stimulation; this
memory reduced rather than increased their proliferation
[62]. These findings underscore epigenetics and chromatin
structure in controlling long-term responses, including
the generation of CSCs and their phenotypic plasticity
[63]. Whether similar molecular and cellular changes can
be ascribed to the TNF long-lasting action remains to be
investigated. However, TNF was shown to induce EMT
and to create a permissive environment for a non-CSC to
CSC conversion in breast cancer [64], and our data do
not exclude the possibility that this mechanism could be
responsible for the TNF-induced changes in the melan-
oma SC compartment. Notably, recent data provided evi-
dence for cell competition as yet another mechanism
leading to the selection and expansion of the best-fitted
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cell (review see [65-67]), which could theoretically also be
responsible for the selection of the best-fitted melanoma
SC in the TNF environment and their post-TNF expan-
sion. Nevertheless, although the above mechanisms are
possible, in the absence of evidence, these mechanisms
remain yet to be proven options.
The TNF-induced differentiation repressing mechanism,
which is mediated by the PI3K/AKT signaling pathway,
seems to be the most probable explanation of our results
and is strongly supported by the findings of other re-
searchers. For example, TNF was shown to induce the
reversible dedifferentiation of melanoma cells [35] and an
increased melanocyte number while inhibiting their
differentiation-related pigmentation [68]. Similarly, TNF
promotes neural stem (NSC) cell proliferation but inhibits
their differentiation [69] and maintains osteosarcomas
in their undifferentiated state [70]. Additionally, in the
hematopoietic system, TNF was shown to have a stimula-
tory growth effect on hematopoietic stem cells (HSCs) but
to negatively regulate the growth of their more mature
progenitors in vitro [71]. In contrast, recent findings re-
vealed that TNF suppresses cycling HSCs and their long-
term repopulating activity in vivo [72] and in vitro [73],
indicating that although the TNF pathway is a critical
regulator of HSC maintenance and function (reviewed in
[47]), the stimulatory and/or repressive effect of TNF will
depend on cell types, the responding compartment and
the cell status within each compartment. Little is known
concerning the effect of TNF on the melanoma SC com-
partment. We [34] and others [74] have shown that this
compartment is heterogeneous and, as we suggested, that
this compartment is composed of CSCs in at least 3 differ-
ent states: quiescent, slow-cycling and fast-cycling, which
are each identified by distinct phenotypes and which
each have a different mode of response to environmental
changes. Roesch et al. [74] determined that the slow-
cycling melanoma cells, which were identified in our study
as GFPhigh cells, have the particular ability to switch be-
tween these phenotypes by assuming a distinct epigenetic
state regulated by histone demethylase. Melanoma tumor
growth depends on the presence of these cells. Consist-
ently, the GFPhigh cells in our reconstitution assay using
an in vivo-like skin equivalent model were significantly
more efficient in reproducing pigmented lesions resem-
bling melanoma in vivo than their faster proliferating
counterparts. This ability was suppressed by TNF, which
simultaneously induced the number of melanosphere-
inducing GFPhigh cells. In melanospheres, these cells co-
existed with their GFPlow progeny and persisted, although
many divisions were required to form a melanosphere.
This finding indicates that TNF, while blocking the differ-
entiation fate of slow-cycling cells, reverses at least some
of these cells into a quiescent state to prevent their ex-
haustion. These data strongly suggest that TNF maintains
melanoma SCs in their primitive state and controls their
plasticity. One pathway that is responsible for this effect is
PI3K/AKT signaling, which regulates stemness in many
stem cell systems [38] and was shown to be selectively
inactivated in one of the symmetrically dividing cells to in-
duce quiescence in one daughter while another continues
to divide [75].
Conclusions
In conclusion, we determined that transient TNF sup-
presses the PI3K/AKT-mediated melanoma SC differen-
tiation and enlarges a GFPhigh melanosphere-initiating
CSC subpopulation that preserves the TNF-instigated
changes, reinforcing their post-TNF capacity to form
tumor-like melanospheres. These findings may have im-
portant clinical consequences because an acute inflamma-
tion may activate and expand pre-existing altered cells
that remain clinically silent for generations until these
cells emerge in a post-inflammatory environment as a pri-
mary or metastatic tumor in a more aggressive form.
Materials and methods
Cell line and cell culture
The human cutaneous melanoma cell line HBL was
established in Professor Ghanems laboratory from a
nodular malignant melanoma [76]. These cells were
maintained in RPMI (Gibco®, Life Technologies™, France)
supplemented with 10% fetal bovine serum (FBS) (Lonza,
Verviers, Belgium) and 1% penicillin/streptomycin (Gibco®,
Life Technologies™, France) in a humidified 5% CO2 incu-
bator at 37°C. The medium was changed every 3 days. The
SK-Mel28 cells were purchased from ATCC (HTB-72) and
grown as recommended. Primary keratinocyte and fibro-
blast cultures were established using specimens of adult
skin discarded after breast plastic surgery (Hôpital Roger
Salengro, CHRU, Lille, France) as described previously
[77]. The storage and use of human biological samples
were declared and performed according to the local
Persons Protection Committee and to the ethical rules
approved by the Department of Health, France. Keratino-
cytes were maintained in defined K-SFM (Gibco®, Life
Technologies™, France) supplemented with 1% penicillin/
streptomycin (Gibco®, Invitrogen™, France). Fibroblasts
were cultured in RPMI supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin.
Construction of plasmids and generation of stable
transfectants expressing inducible H2B-GFP
To accomplish the tetracycline-inducible expression of
fused histone 2B-green fluorescent protein (H2B-GFP),
we cloned the Taq polymerase-amplified H2B-GFP gene
from Addgene into the PCR8/GW/TOPO entry vector
and then into the pT-Rex DEST30 destination vector
using the Invitrogen Gateway cloning system and Clonase
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II enzyme mix. The constructed pT-Rex DEST30-H2B-
GFP plasmid was used for the Lipofectamine-mediated
transfection of human melanoma HBL and SK-Mel28
clones that were previously modified and preselected in
the 0.5 μg/ml blasticidin-containing medium to express
high levels of tetracycline-sensitive repressor (TetR) from
the pcDNA 6/TR Invitrogen plasmid. HBL and SK-Mel28
cells expressing both plasmids were preselected in 400 μg/
ml geneticin (G418 sulfate) and 0.5 μg/ml blasticidin and
cloned using serial dilution assay. The presence of two
plasmids, pT-Rex DEST30-H2B-GFP and pcDNA 6/TR,
in the individual clones was verified by RT-PCR, and
H2B-GFP expression was confirmed by flow cytometry.
To induce H2B-GFP expression, cells were incubated
for 24 h with 1 μg/ml tetracycline, which inactivated
TetR and derepressed the tetracycline operator 2X TetO2
(Tet-ON system), permitting H2B-GFP transcription from
the CMV promoter. Clones that expressed high, but not
toxic, levels of H2B-GFP were chosen for further experi-
mentation. Stably transfected cells were grown in the pres-
ence of blasticidin and geneticin to maintain TetR and
H2B-GFP genes. Blasticidin was obtained from Gibco®,
Life Technologies™, France, and geneticin was obtained
from Santa Cruz Biotechnology. RNA extraction was per-
formed following the manufacturers protocol (RNeasy
Kit, Qiagen, Courtaboeuf, France). Primers were designed
to amplify 305 bp cDNA fragments for the pcDNA6/TR
plasmid and 187 bp cDNA fragments for the pT-Rex
DEST30-H2B-GFP plasmid as follows: 1st plasmid: 5
CTGGTCATCATCCTGCCTTT3 and 5GGCGAGTTT
ACGGGTTGTTA3; 2nd plasmid: 5ACGTAAACGGCC
ACAAGTTG3 and 5AAGTCGTGCTGCTTCATGT
G3. RNA was transcribed into cDNA using random
hexamers, recombinant RNasin® ribonuclease inhibitor
(Promega, France) and M-MLV reverse transcriptase
(Promega, France). PCR was performed using GoTaq®
Flexi DNA polymerase (Promega, France).
Generation of melanospheres
To generate primary spheres, 4 × 103 cells were plated on
24-well plates coated with a 0.5 mg/ml poly-2-hydro-
xyethylmetacrylate (polyHEMA) ethanol solution (Sigma-
Aldrich, France) to prevent cell attachment and cultured
in DMEM/F12 medium (Gibco®, Life Technologies™,
France), which was supplemented with 20 ng/ml EGF
(Stem Cells Biotechnologies, Vancouver, BC, Canada),
1:50 B27-supplement (Gibco®, Invitrogen™, France),
and 20 ng/ml rHu bFGF (PromoKine-PromoCell GmbH,
Heidelberg, Germany), in a humidified 5% CO2 incubator
at 37°C for 7 days. Tumor Necrosis Factor α (TNF)
(0.5 μg/ml) from Immunotools, Germany, and/or an in-
hibitor of the PI3K/AKT signaling, 10 μM LY294002, or
an inhibitor of NFκB signaling, 1 μM BAY 117082, which
were both obtained from Calbiochem, France, were added
at the time of sphere seeding and not re-added during the
7 days of sphere formation. Spheres were dissociated by
a brief incubation with trypsin/EDTA solution (Gibco®,
Life Technologies™, France) and then used as a single
cell suspension for all the experiments. Cell viability was
evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) assay (Sigma-Aldrich,
France). After complete solubilization, the presence of
blue formazan was evaluated spectrophotometrically by
measuring the absorbance at 562 nm. For the LRC-
assay, cells were treated with tetracycline (1 μg/ml) for
24 hours at 37°C in adherent culture and plated as above.
Spheres (larger than ~50 cells) were counted under the
microscope, and sphere-forming units (SFUs) (%) were
estimated according to the formula: number of spheres/
number of plated live cells × 100.
Flow cytometry
Spheres containing GFPhigh cells were dissociated, and
single cell suspensions (2 × 105 cells/500 μl) of HBL
or SK-Mel28 cells were incubated for 45 min on ice
in 100 μl of RPMI medium with the following pri-
mary antibodies: anti-ABCB5 (Rockland, Tebu-Bio,
France), which was used at a 1:215 dilution, and anti-
VEGFR1 (Abcam), anti-Notch (Santa Cruz Biotech),
and anti-CD57 (HNK-1) (gift from Dr E. Dupin, Vision
Institute, Paris or from Santa Cruz Biotech), which
were used at a 1:50 dilution. After incubation, the
cells were rinsed with RPMI, centrifuged and resus-
pended in 100 μl of RPMI with a secondary antibody,
Cy5® goat anti-rabbit IgG (H + L) or goat anti-mouse
(Molecular Probes®, Life Technology™, France), which
was used at a 1:2000 dilution for 30 min on ice in
dark. After incubation, the cells were rinsed with RPMI,
centrifuged, resuspended in 500 μl of RPMI, and placed
on ice before being analyzed by flow cytometry. Propi-
dium iodide (PI)-positive dead cells were gated out and
excluded from the analysis. Acquisition was performed
on an EPICS-CYAN flow cytometer (Beckman Coulter
France S.A.S.) and analyzed using Summit 4.3 software.
GFP fluorescence intensities were recorded on the FL1
channel. Quadrants were determined based on nega-
tive control staining with a corresponding isotype
antibody. FACS sorting: Cell sorting was performed
on an FACS-ALTRA sorter (Beckman Coulter France
S.A.S.). Spheres were dissociated, and the single cell
suspension was adjusted to a concentration of 106
cells/ml in RPMI. After excluding cell debris, the
collection gates were set according to the negative
(GFPlow) control containing cells untreated with tetra-
cycline. Cells with positive fluorescence constituted
the GFPhigh cell subset. The collected cells were cen-
trifuged, rinsed and re-plated for sphere and colony
generation.
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Generation of human skin equivalents
Skin equivalents (SEs) were prepared as described previ-
ously [78]. Briefly, dermal equivalents (DEs) were pre-
pared using primary human fibroblasts (3 × 105/DE) in
RPMI with heat-deactivated fetal bovine serum (FBS),
1 mM NAOH and collagen I (rat tail collagen type I, BD
Biosciences, France), which were placed into 6-well
plates and allowed to contract for several days until their
radii reached 5 mm. To regenerate melanoma cells in a
reconstructed epidermis, a mixture of primary keratino-
cytes (1 × 105/SE) and 1 × 104/SE human melanoma cells
with or without sorting were seeded onto DEs and cul-
tured for 7 days in DMEM (Gibco®, Life Technologies™,
France) supplemented with 10% FBS in the presence or
absence of 0.5 μg/ml TNF. Then, the cultures were lifted
at the air-liquid interface to stimulate keratinocyte differ-
entiation. The medium, which was supplemented with
0.5 μg/ml hydrocortisone, was changed every 23 days.
After 2123 days of culture, skin equivalents were disso-
ciated using 4 mg/ml collagenase for 30 min at 37°C and
trypsin/EDTA for an additional 5 min. Then, melanoma
cells were counted and plated on 24-well plates coated
with polyHEMA in DMEM/F12 for sphere formation.
EdU incorporation by melanosphere cells
An Alexa Fluor® 647 Click-iT Edu Flow Cytometry Assay
Kit (Life Technologies) and its accompanied recommen-
dations were used to estimate the proportion of GFP-
positive and -negative melanosphere cells in S phase.
Non-cytotoxic 10 μM EdU (5-ethynyl-2-desoxyuridine)
was added for 2 hours to melanosphere cultures before
harvesting. Melanospheres were dissociated with trypsin/
EDTA, and a suspension of 1 × 106 individual cells was
centrifuged, washed twice with PBS/1% BSA buffer and
fixed in 4% paraformaldehyde solution for 15 minutes at
RT in the dark. The fixed cells were permeabilized with
saponin solution and incubated with Alexa Fluor® 7
azide in the supplied buffer for 30 minutes in the dark.
Labeled cells were analyzed by flow cytometry. For
the detection of EdU with Alexa Fluor® 647 azide, we
used 633/635 nm excitation with a red emission filter
(660/620 nm). The proportion of melanoma cells that
were both EdU-positive and GFP-positive or GFP-negative
was estimated by a flow cytometry quadrant analysis de-
termining the percentage of each subpopulation. Negative
control was gated using EdU unstained and tetracycline
uninduced cells.
Immunocytochemistry
HBL-H2BGFP melanospheres were cultured for 7 days
in the presence or absence of TNF (0.5 μg/ml) and/or
LY294002 (10 μM), which were both added at seeding.
The dissociated melanosphere cells were plated on Lab-
Tek chamber glass coverslips (Millicell EZ SLIDE 8-well
glass, sterile Merck Milipore, Darmstadt, Germany) at a
density of 15 000 cells per well. After 24 hours, the
adherent cells were fixed in PAF solution, and immuno-
cytochemistry was performed according to the standard
procedure. A monoclonal anti-Melan A antibody, which
was purchased from Santa Cruz Biotech, was used at
a dilution of 1:100, and positive cells were detected
with a secondary AlexaFluor 594 goat anti-mouse (Life
Technologies), which was used at a dilution of 1:2000.
Negative controls were performed by replacing the primary
antibody with an irrelevant isotype. Nuclei were counter-
stained with DAPI. All slides were mounted under a
coverslip with Vectashield mounting medium (Vector
Laboratories, Nanterre, France) and were photographed
using a Leica DMRB LAS3.7 fluorescence microscope.
Western blot analysis
Western blot analysis was performed using ready-to-use
NuPAGE 4%12% BisTris polyacrylamide gels accord-
ing to the suppliers instructions (Invitrogen™, St. Aubin,
Paris, France). Blots were probed with the primary anti-
bodies against Actin (Sigma-Aldrich, St. Quentin Fallavier,
France), Akt and pAkt (Cell Signaling, France), followed
by a horseradish peroxidase-conjugated secondary anti-
body (Bio-Rad, Marne-la-Coquette, France). Correspond-
ing isotypes were used as controls. Immunodetection was
performed using an ECL + chemiluminescence kit from
Amersham. The band intensities in immunoblotting were
analyzed and quantified using ImageJ and user-supplied
algorithms.
Statistical analysis
The results are expressed as the mean ± standard error of
the mean (SEM) of at least 3 independent experiments
each combining spheres from 24 wells unless indicated
otherwise. A comparison between means was performed
using Students t-test for unpaired data. When unequal
variance was observed, Welchs correction was applied. A
comparison between several groups was performed using
a one-way analysis of variance, followed by Dunnetts mul-
tiple comparison test, using an appropriate control group
as the reference. The statistical analyses were performed
using GraphPad Prism 4.0 software. A p value of < 0.05
was considered significant.
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